Starling Oncology, Inc. Stock: price and insider trades · United States
1 insider bought €68k of shares over the last 90 days, the latest by Chernett Jorey, filed 17 Aug 2026.
Who traded when
BuySale+5 other insiders
Since the insiders bought
- +3.6%Entry US$6.40 · Close at T+30 US$6.63
- +48.4%Entry US$2.50 · Close at T+365 US$3.71
- +148.2%Entry US$1.14 · Close at T+365 US$2.83
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Starling Oncology, Inc. Strong Buy (bullish), based on 4 analysts. Average price target: US$9.75.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- 298,853 shares@ US$6.51260.28% mcap19.1% of flowCommon StockSEC:0001079973-26-001175:0
- 298,853 shares@ US$6.540.28% mcap100.0% of flowCommonSEC144:0001950047-26-008532
- 12,000 shares@ US$6.540.012% mcap3.1% of flowCommon StockSEC:0000921895-26-002203:0Canonical exit: 12 Nov 2026 (T+90)
- 31,124 shares0Common StockSEC:0001079973-26-000987:0
- 27,108 shares0Common StockSEC:0001079973-26-000983:0
- 31,124 shares0Common StockSEC:0001079973-26-000981:0
- 30,120 shares0Common StockSEC:0001079973-26-000989:0
- 29,116 shares0Common StockSEC:0001079973-26-000985:0
- 33,133 shares0Common StockSEC:0001079973-26-000993:0
- 41,165 shares0Common StockSEC:0001079973-26-000991:0
- 18,000 shares@ US$5.275.0% of flowCommon StockSEC:0000921895-26-001852:0Canonical exit: 19 Oct 2026 (T+90)
- 17,974 shares@ US$1.8712.1% of flowCommon StockSEC:0001553350-26-000111:0
- 17,974 shares@ US$6.42941.5% of flowCommon StockSEC:0001553350-26-000111:1
- 5,478 shares@ US$2.003.9% of flowCommon StockSEC:0001553350-26-000111:2
- 5,478 shares@ US$6.3512.5% of flowCommon StockSEC:0001553350-26-000111:3
- 23,452 shares@ US$6.250.029% mcap56.5% of flowCOMMONSEC144:0001950047-26-007065
- 15,000 shares@ US$5.854.6% of flowCommon StockSEC:0000921895-26-001798:0Canonical exit: 8 Oct 2026 (T+90)
- 25,833 shares0Common StockSEC:0001079973-26-000939:0
- 17,185 shares0Common StockSEC:0001079973-26-000940:0
- 18,000 shares@ US$5.024.4% of flowCommon StockSEC:0000921895-26-001657:0Canonical exit: 21 Sept 2026 (T+90)
- 23,451 shares@ US$4.8743.5% of flowCOMMONSEC144:0001950047-26-005778
- 12,000 shares@ US$4.752.9% of flowCommon StockSEC:0000921895-26-001564:0Canonical exit: 2 Sept 2026 (T+90)
- 1,604 shares@ US$4.477.8% of flowCommon StockSEC:0001079973-26-000723:0
- 5,000 shares@ US$4.051.0% of flowCommon StockSEC:0000921895-26-001466:0Canonical exit: 17 Aug 2026 (T+90)
- 33,500 shares@ US$4.077.0% of flowCommon StockSEC:0000921895-26-001466:1Canonical exit: 18 Aug 2026 (T+90)
25 of 336 declarations
About Starling Oncology, Inc.
Starling Oncology, Inc., a US healthcare company valued at USD 658 million and 17.8% held by insiders, shows 93 sales worth EUR 51,771,599 (median EUR 114,180) and 41 purchases worth EUR 4,071,360 (median EUR 34,980), which is 31% of open-market trades. The 336 filings start on March 17, 2020 and the latest is dated August 24, 2026.
The largest sale is M33 Growth I L.P.'s (Director), EUR 15,952,884 on September 4, 2025; Richy Agajanian sold EUR 7,685,520 on May 11, 2022 and Brad Hively (Director) EUR 4,708,686 on June 3, 2025. Havencrest Healthcare Partners, L.P. (10% Owner) is the most frequent filer, with 72 filings, 68 of them sales. On March 26, 2025, eight filers bought EUR 1,534,792, including Richard A. Barasch (Director) for EUR 1,311,793; Jorey Chernett bought EUR 666,536 on March 13, 2026 and EUR 334,924 on March 24, 2026.
Read moreShow less
The 39 purchases tracked at 90 days have a stored median of 41.7%, with 62% positive: stored past results, not a forecast. The annual peak is 109 in 2022; the last twelve months hold 74 filings, of which 15 purchases and 10 sales.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
